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Abstract
The objective of this study is to report the clinical characteristics and treatment of patients with progressive cerebellar
ataxia associated with anti-GAD antibodies. We performed a retrospective review of all patients with anti-GAD ataxia
managed at the Sheffield Ataxia Centre over the last 25 years. We identified 50 patients (62% females) with anti-GAD
ataxia. The prevalence was 2.5% amongst 2000 patients with progressive ataxia of various causes. Mean age at onset
was 55 and mean duration 8 years. Gaze-evoked nystagmus was present in 26%, cerebellar dysarthria in 26%, limb
ataxia in 44% and gait ataxia in 100%. Nine patients (18%) had severe, 12 (24%) moderate and 29 (58%) mild ataxia.
Ninety percent of patients had a history of additional autoimmune diseases. Family history of autoimmune diseases was
seen in 52%. Baseline MR spectroscopy of the vermis was abnormal at presentation in 72%. Thirty-five patients (70%)
had serological evidence of gluten sensitivity. All 35 went on gluten-free diet (GFD). Eighteen (51%) improved, 13
(37%) stabilised, 3 have started the GFD too recently to draw conclusions and one deteriorated. Mycophenolate was
used in 16 patients, 7 (44%) improved, 2 stabilised, 6 have started the medication too recently to draw conclusions and
one did not tolerate the drug. There is considerable overlap between anti-GAD ataxia and gluten ataxia. For those
patients with both, strict GFD alone can be an effective treatment. Patients with anti-GAD ataxia and no gluten
sensitivity respond well to immunosuppression.
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Introduction
Glutamic acid decarboxylase (GAD) is the rate-limiting en-
zyme in the synthesis of the inhibitory neurotransmitter
gamma-aminobutyric acid (GABA). GAD is found in both
the central and peripheral nervous systems (including the en-
teric nervous system) as well as in pancreatic beta cells [1].
Antibodies against pancreatic islet cell proteins were first de-
tected in children with insulin-dependent diabetes mellitus
(IDDM) and were subsequently characterised as GAD anti-
bodies [2–4]. Twomajor types of GAD enzyme exist, GAD65
and GAD67. These catalyse the formation of GABA at differ-
ent cell locations and different time periods of development.
The GAD67 enzyme is widespread in the central nervous
system, whilst GAD65 is confined to nerve terminals.
GABA is synthesised by GAD67 for neuronal activity unre-
lated to neurotransmission and synaptogenesis. On the other
hand, GAD65 produces GABA for neurotransmission and is
required at synapse [5].
The first neurological disease to be linked with GAD65
antibodies was stiff-person syndrome (SPS) [6]. GAD anti-
bodies were subsequently shown to be present in the sera of
up to 60% of patients with SPS, 80% of patients with IDDM
(at a much lower titre than SPS), in patients with
polyendocrine autoimmune syndromes and in some cases of
sporadic, otherwise idiopathic ataxia [7–11].
The first case series of patients with so-called anti-GAD
ataxia was published in 2001 [12]. It has since been common
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practice to include anti-GAD antibody testing in the diagnos-
tic workup of all patients with progressive idiopathic ataxia.
The presence of high titre of anti-GAD antibodies should alert
the possibility of an immune-mediated ataxia and the need to
consider immunosuppressive treatment.
We have previously demonstrated significant overlap be-
tween anti-GAD-associated neurological diseases and gluten
sensitivity [13]. Here, we present our 25-year experience of
managing 50 patients with anti-GAD ataxia at the Sheffield
Ataxia Centre.
Methods
This report is based on a retrospective observational case se-
ries of patients regularly attending the Sheffield Ataxia
Centre. The South Yorkshire Research Ethics Committee
has confirmed that no ethical approval is indicated given that
all investigations/interventions were clinically indicated and
did not form part of a research study.
Patients
We performed a retrospective review of all patients with pro-
gressive ataxia and high serological titres of GAD antibodies
(defined as > 2000 U/ml, normal < 5). Estimation of anti-
GAD was made using a commercial assay (RSR Limited)
according to the manufacturers’ instructions. Briefly, the wells
are coated with GAD 65, and the samples are added and in-
cubated. GAD65-biotin is added to the wells and incubated.
Streptavidin-peroxidase is added to the wells. TMB substrate
is added and incubated, and the plate is read at 405 nm (if low
values, it is also read at 450 nm). Plate also includes calibra-
tors 2000, 250, 120, 35, 18 and 5 U/mL and positive and
negative control samples. The wells are washed in between
each stage.
All patients have been seen, and most are still under active
follow-up at the Sheffield Ataxia Centre, Sheffield, UK. All of
these patients have been extensively investigated for other
causes of ataxia including extensive genetic testing using
next-generation sequencing [14]. The review included de-
tailed examination of the clinical records and MR imaging
including MR spectroscopy (MRS) of the cerebellum. This
technique is under regular clinical use at our centre as a mon-
itoring tool for all patients with progressive ataxia, particularly
those undergoing therapeutic interventions [15]. In these se-
ries of 50 patients, we have only included patients presenting
with cerebellar ataxia and excluded patients with SPS, the
other group of patients seen in neurology clinics that often
have high titres of anti-GAD antibodies.
Results
Clinical Characteristics
We identified 50 patients with anti-GAD ataxia (anti-GAD >
2000 U/ml, normal < 5). Sixty-two percent were female. The
prevalence of anti-GAD ataxia amongst 2000 patients with
progressive ataxia of various causes attending the Sheffield
Ataxia Centre was 2.5%. Mean age at onset of the ataxia
was 55 years (range 13–88) and mean duration 8 years (range
1–24). Gaze-evoked nystagmus was seen in 26%, cerebellar
dysarthria in 26%, limb ataxia in 44% and gait ataxia in 100%.
Using an established simple rating scale for severity of ataxia,
9 patients (18%) had severe ataxia (wheelchair bound), 12
(24%) moderate (needed walking aid) and the remainder 29
(58%) mild (could walk unaided) [16]. Twenty-four patients
(48%) had autoimmune thyroid disease and 18 (36%) had
IDDM.Other autoimmune diseases (excluding coeliac disease
and gluten sensitivity) were seen in 13 patients (26%—6 per-
nicious anaemia, 3 Sjogren’s syndrome, 1 giant cell arteritis, 1
vitiligo, 1 Lambert-Eaton myasthenic syndrome, 1 myasthe-
nia gravis). Only 5 patients (10%) had no evidence of addi-
tional autoimmune diseases. Family history of autoimmune
diseases (first-degree relatives) was present in 52%. Thirty-
five patients (70%) had serological evidence of gluten sensi-
tivity, and 26 of these underwent gastroscopy and duodenal
biopsy. Ten had coeliac disease on duodenal biopsy (villus
atrophy, crypt hyperplasia and increased intraepithelial lym-
phocytes). The clinical characteristics of the complete cohort
are summarised in Table 1.
Table 1 Clinical characteristics of 50 patients with anti-GAD ataxia
Total number of patients with anti-GAD ataxia 50
(62% female)
Mean age at onset of ataxia 55 years (range 13–88)
Mean duration of ataxia 8 years
(range 1–24)







Additional autoimmune diseases 90%
Family history of autoimmune diseases 52%
Serological evidence of gluten sensitivity 70%
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Imaging
Baseline MRI and MRS was available in 47/50 patients.
Cerebellar vermian atrophy was present in 47% and cerebellar
hemispheric atrophy in 36%. The atrophy of the vermis was
graded as 1 (mild) in 15 of the patients, and the hemispheric
atrophy was graded as 1 also in 15 patients. This meant that
only 7 patients had either moderate or severe vermian atrophy
with only 2 having moderate atrophy of the hemisphere.
Progression of any atrophy over time was only observed in
2 patients.
The mean value of NAA/Cr ratio was reduced across the
cohort at 0.892 (median 0.9, IQR 0.133). Thirty-four out of 47
(72%) patients had abnormal MRS of the vermis at the time of
initiation of treatment, in keeping with what is often seen in
immune-mediated ataxias [17].
Neurophysiology
Neurophysiological assessments were done according to clin-
ical indications. Twelve patients (24%) had clinical evidence
of myoclonus which on EEG/EMGpolygraphy recordings and
quantitative analysis with jerk-locked averaging revealed a
cortical generator of the myoclonus in three (2 had gluten
sensitivity and one had IgA deficiency). The recording meth-
odology and quantitative data analysis for the electrophysio-
logical assessment of myoclonus is described in detail in pre-
vious publications [18]. Somatosensory evoked potential
(SEP) recordings were also undertaken [19]. The possibility
of long loop reflexes (C-reflexes) to look for stimulus sensitive
myoclonus was examined with surface EMG electrodes in the
leg and arm areas using published methodology [20]. Only one
patient was found to have “giant” SEPs from the upper limbs
but without any evidence of reflex myoclonus. Four patients
were found to have large fibre axonal peripheral neuropathy on
nerve conduction studies, one had evidence of LEMS (not
suspected clinically) and one had typical features of SPS (con-
tinuous motor unit activity on needle EMG of paraspinal mus-
cles) but without associated typical clinical features. One of the
patients with electrophysiological evidence of cortical myoc-
lonus also had on EMG polygraphy features of exaggerated
auditory physiological startle responses elicited by unanticipat-
ed loud auditory stimuli at 100 dB. No habituation was seen
despite the procedure was repeated on numerous occasions
over short intervals of time, and consistently lower limb mus-
cles were activated during the acoustic startle.
Effect of Treatment
The 35 patients with serological evidence of gluten sensitivity
(with and without coeliac disease) received detailed dietetic
advice on strict adherence to a gluten-free diet (GFD). This
was along the same lines as advice given for the treatment of
gluten ataxia (GA) [21]. In 18 of the 35 (51%) patients with
anti-GAD ataxia who also had gluten sensitivity, the ataxia
improved onGFD alone, in 13 (37%) stabilised, and 3 patients
have started the GFD too recently to draw conclusions. One
patient continued to deteriorate despite GFD. Determination
of clinical improvement/deterioration was based on clinical
evaluation (repeated neurological examination during clinic
attendances) and the patient’s own perception about their atax-
ia symptoms.
Mycophenolate was used in 16 patients (13 of which also
had gluten sensitivity), 7 (44%) of which improved, 2
stabilised, 6 only recently started the medication and one did
not tolerate mycophenolate. Only those patients with gluten
sensitivity who stabilised but did not improve and the one who
worsened despite GFD went on to be treated with
mycophenolate.
At the time of starting treatment, the mean NAA/Cr ratio
was 0.883 (median 0.9, IQR 0.115). Follow-up MRS after
treatment was available in 20 patients to date with mean
follow-up interval of 2.75 years (median 2 years and IQR
2.5 years). In keeping with clinical improvement, the follow-
upMRS improved after treatment in 16 (14 on GFD alone and
2 on mycophenolate), worsened in 3 and was unchanged in 1.
The mean NAA/Cr ratio after treatment for the 16 patients that
improved increased to 0.954 (median 0.975, IQR 0.15) which
was now within the normal range. Clinical improvement was
observed in all 16 patients with increased NAA/Cr ratio on
MRS. This was in keeping with what we have already pub-
lished, that is, significant positive correlation between MRS
and clinical improvement as assessed by the scale for assess-
ment and rating of ataxia (SARA) [15, 22].
Three patients (not gluten sensitive) received intravenous
immunoglobulins but with no evidence of sustained improve-
ment. One patient received rituximab after no response to
intravenous immunoglobulins, partial response to mycophe-
nolate and cyclophosphamide (see illustrative clinical case).
Another patient also received cyclophosphamide with good
response. Only 9 of the 50 patients did not have any therapeu-
tic intervention. This was either due to patient choice (6) or
due to no clinical and MR spectroscopy evidence of disease
progression (3).
Overall treatment with GFD and/or immunosuppression
was associated with clinical improvement or stabilisation in
84% of those patients treated.
Illustrative Clinical Case
A 50-year-old lady presented initially to audiovestibular med-
icine with a history of dizziness and vertigo in 1996.
Investigations at the time did not identify any inner ear pathol-
ogy; hence, she was referred to neurology for further evalua-
tion. There was a past history of hypothyroidism and no fam-
ily history of any neurological illness. She complained
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primarily of gait instability but was able to walk without walk-
ing aids and had no falls. Clinical examination showed some
difficulties in tandem walking in keeping with gait ataxia but
no other neurological dysfunction. Investigations at the time
(including genetic testing) and MRI were normal. CSF exam-
ination showed normal protein, no cells and was negative for
oligoclonal bands. She was monitored on a 6 monthly basis
with little evidence of any progression. In 2002 at the age of
56 she developed IDDM and started insulin injections. In
2003 she was tested for the first time for anti-GAD antibodies
and was positive with titres > 2000 U/ml. Despite the absence
of any serological evidence of gluten sensitivity, she tried
GFD for a year without any evidence of clinical improvement.
Close monitoring with clinical evaluation of her ataxia
showed that her balance was getting worse (although still able
to walk using a stick) as a result of which in 2006 she had 2
courses of intravenous immunoglobulins without any evi-
dence of improvement. In 2009 she was found to have low
vitamin B12 (positive intrinsic factor) and started on B12 in-
jections. After a period of stability, she again started deterio-
rating during 2011 when in addition to the progression of gait
ataxia she complained of vertigo. Examination showed no
evidence of vestibular pathology to account for the vertigo.
In 2011 she underwent MR spectroscopy assessment of the
cerebellum for the first time. In 2013 she started treatment
with mycophenolate resulting in clinical stabilisation with
MR spectroscopy evidence of improvement in NAA/Cr ratio
of the vermis (Fig. 1). The patient, however, did not experi-
ence any clinical improvement, and 2 years later at her re-
quest, she stopped the mycophenolate. A few months later,
there was a sudden deterioration that occurred during a sum-
mer holiday (2015). Investigations showed no concurrent in-
fection on any other pathology to be contributing to the sud-
den deterioration. Repeat MR spectroscopy showed a signifi-
cant drop of NAA/Cr from the vermis. She was treated with
pulses of cyclophosphamide which again resulted in clinical
stabilisation and improved MR spectroscopy. In early 2018,
she received the first course of rituximab, and this was repeat-
ed later on in that year. This was again accompanied by MR
spectroscopy improvement. Unfortunately by this stage, she
had become significantly disabled due to cerebellar tremor
that affected both arms and head. She had become largely
wheelchair dependent. She decided not to continue with ritux-
imab and is awaiting deep brain stimulation procedure to help
with her disabling tremor. MR imaging at this stage (21 years
after initial presentation) showed significant cerebellar atro-
phy (Fig. 2).
Discussion
This report describes our series of patients with anti-GAD
ataxia. Unlike previous smaller reports on the subject, all of
the patients described here were clinically assessed and man-
aged at the same centre, by the same team, being diagnosed
after attending the Sheffield Ataxia Centre [23, 24]. A novel
Fig. 1 N-acetyl aspartate to creatine ratio (NAA/Cr) of the vermis
showing alterations in relation to different treatment interventions. The
patient developed ataxia in 1996, but the diagnosis of anti-GAD ataxia
was not made until 2003. She followed a benign course initially. She did
receive 3 courses of intravenous immunoglobulins in 2005 with no
evidence of clinical benefit. Whilst there was evidence of significant
improvement of the MR spectroscopy with subsequent interventions
(from 2011 onwards, when MR spectroscopy became available), the
patient did not feel that there was a dramatic clinical improvement of
the ataxia and was reluctant to continue such treatments. She now has
severe ataxia with disabling cerebellar tremor
Fig. 2 MRI scan from the illustrative case discussed in the text taken in
2020, which was 23 years after the original presentation. Whilst the
baseline scan was normal, the scan above demonstrates significant
atrophy of both the vermis and the hemisphere
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inference is the significant overlap of anti-GAD and GA, as
70% of patients with anti-GAD ataxia had serological evi-
dence of gluten sensitivity and the majority responded to
GFD a l o n e w i t h o u t n e c e s s i t a t i n g t h e u s e o f
immunosuppression.
There was a high prevalence of additional autoimmune
diseases (90% of patients) and a family history of autoimmune
diseases in first-degree relatives in 52%. This suggests that
anti-GAD antibodies are a marker of multiple autoimmunity
of which the cerebellar ataxia may be one of many autoim-
mune manifestations.
The association between anti-GAD antibodies, multiple
autoimmunity and gluten sensitivity merits close consider-
ation. Italian researchers have noted that the prevalence of
additional autoimmune diseases in children with coeliac dis-
ease (CD) is significantly lower than in those patients with CD
diagnosed in adulthood [25]. They concluded that GFD may
reduce the risk of developing additional autoimmune diseases
later on in life. This observation echoes our observed reduc-
tion in anti-GAD antibodies in patients with anti-GAD-related
diseases and gluten sensitivity who go on a strict GFD [13].
Our results also highlight the preferential involvement of
the cerebellar vermis, something that is commonly seen in
immune-mediated ataxias [26]. The severity of anti-GAD
ataxia by comparison to some degenerative (MSA-C) or ge-
netic ataxias (SCA6) and some other immune-mediated
ataxias (paraneoplastic cerebellar degeneration) seems, by
comparison, mild. Indeed the majority (58%) had mild ataxia
at presentation with only 18% having severe ataxia. The mild
ataxia was also reflected in the MR spectroscopy measure-
ments and the degree of cerebellar atrophy. However, if pa-
tients with anti-GAD ataxia remain untreated, their ataxia is
generally progressive, with accumulation of significant dis-
ability over time. Treatment benefits most patients, but treat-
ment should be considered at an early stage in an attempt to try
and prevent the accrual of irreversible disability. The illustra-
tive case reported here highlights this issue as the patient was
not treated for 17 years, partly because the diagnosis of anti-
GAD ataxia was made late. Her mild, slowly progressive
ataxia seemed insufficient to justifying the use of immunosup-
pression for many years. This emphasises close clinical and
MR spectroscopic monitoring, with a low threshold for treat-
ment which is essential in preventing permanent disability. Of
note is the slowly progressive course for years but with sudden
and often severe irreversible exacerbations (as illustrated by
the case report). This is another justification for early thera-
peutic intervention.
The pathological role of anti-GAD antibodies in the gene-
sis of this immune ataxia is unclear. Since GAD65 is intracel-
lularly located and is associated with a range of neurological
conditions (ataxia, SPS, epilepsy) as well as IDDM, some
have argued that anti-GAD65 antibodies have no pathogenic
role to play. On the other hand, recent physiological studies
in vitro and in vivo have demonstrated that binding of GAD65
by anti-GAD65 antibodies induces loss of GAD65 functions
relating to GABA release, with an epitope dependence, lead-
ing to the development of cerebellar ataxia [27]. Given these
observations, the question still remains as to why is GFD
beneficial in those patients with gluten sensitivity and anti-
GAD ataxia. The significant overlap between anti-GAD atax-
ia and gluten sensitivity also raises important considerations
for anti-GAD pathogenicity. The response of anti-GAD ataxia
to GFD in those patients who are gluten sensitive suggests that
gluten sensitivity is part of the underlying pathogenesis.
Furthermore, previous work from our group has highlighted
a link between neurological manifestations of gluten sensitiv-
ity and anti-GAD antibodies, demonstrating reduction of the
titre of anti-GAD antibodies after the introduction of GFD
[13]. Indeed in 2 of the patients with anti-GAD ataxia and
gluten sensitivity reported here, the level of anti-GAD
dropped to below 2000 U/ml following GFD (unpublished
observation). It is possible that such a drop may have been
evident in other patients but the lack of routine quantification
of high titres (> 2000 U/ml) by our clinical immunology lab-
oratory does not allow such confirmation. In gluten ataxia,
elimination of gliadin and transglutaminase (TG2 and TG6-
related antibodies), all of which cross-react with cerebellar
tissue, has a beneficial effect [28]. This would also likely be
true in the context of patients with anti-GAD ataxia who are
gluten sensitive. One possibility is that in these patients there
is double insult causing cerebellar damage, one driven by
gluten and the other by anti-GAD. Eliminating the first by
strict GFD might help the ataxia (as observed here), but per-
haps the combined use of both the GFD and immunosuppres-
sion may result in better overall outcome. In practice we have
reserved the use of immunosuppression for those patients
where GFD alone did not improve the ataxia. We have ob-
served that patients with anti-GAD antibodies and gluten sen-
sitivity proportionally are more likely to require additional
immunosuppression than those patients with gluten ataxia
alone even when both groups are on strict GFD. It is possible
that a more effective approach would be to use both GFD and
immunosuppression together at the time of diagnosis. The
benefits of strict GFD can take up to a year to manifest and
require complete elimination of all gluten-related antibodies
that can only be achieved by strict adherence to GFD. Re-
exposure to gluten causes reactivation of the immune process
that results in cerebellar damage, and such dietary indiscre-
tions may set the patient back for several months. These issues
are challenging for many patients.
Although detailed neurophysiological assessments have
not been done in all patients, there was electrophysiological
evidence of cortical myoclonus in only three, two of which
had serological evidence of gluten sensitivity and one had IgA
deficiency (also suspected as having gluten sensitivity but
negative serology due to the IgA deficiency). Gluten
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sensitivity is a well-recognised cause of cerebellar ataxia with
cortical myoclonus and in this instance could have been a
synergistic factor leading to the development of cortical my-
oclonus [18]. We have described a similar phenomenon in a
cohort of patients with long-term exposure to lithium who
were also gluten sensitive and developed cortical myoclonus
[29]. In addition, our patient with the IgA deficiency was
found to have evidence of exaggerated physiological acoustic
startle responses. This tendency has been previously described
in great detail in patients with SPS [30].
The presence of high titre of anti-GAD antibodies should
not always preclude the investigation for other causes of atax-
ia. We have encountered 3 patients (not included in these
series) with progressive ataxia, positive anti-GAD antibodies
(> 2000 U/ml) but with alternative aetiology for their ataxia.
The clinical suspicion of an alternative aetiology was as fol-
lows: One patient progressed rapidly and developed autonom-
ic dysfunction fulfilling the criteria for probable MSA-C, a
second patient in his 20s had severe global cerebellar atrophy
(unusual for anti-GAD ataxia) which lead to genetic testing
confirming a pathogenic mutation for ANO10 and a third
patient had mild spastic paraparesis and waddling gait which
lead to a genetic diagnosis of SPG7.
Whilst it is extremely rare to find such high levels of anti-
GAD in genetic ataxias (in our genetic ataxia cohort, the figure
for positive anti-GAD was 0.004%) in clinical scenarios
where an alternative diagnosis is suspected examination of
the CSF may prove helpful in demonstrating the intrathecal
production of GAD antibodies thus further supporting the
diagnosis of anti-GAD ataxia [12]. Indeed one may argue that
the absence of a systematic study of the CSF is a limitation of
this report. However, in everyday clinical practice, we found
that high serological levels of anti-GAD in the context of an
idiopathic ataxia were sufficient to diagnose and treat as anti-
GAD ataxia.
Finally, we did not include in these series patients with
SPS. In our experience, patients with SPS almost always have
a degree of cerebellar ataxia, but their primary presentation is
distinct and characterised by axial rigidity and spasms. SPS is
also rare and in our experience less common than anti-GAD
ataxia. Over the same period of time (25 years), we have
encountered 18 patients with classic SPS (another area of
our interest) as compared to 50 patients with anti-GAD ataxia.
However, there may well be some ascertainment bias given
that the patients with ataxia were seen at the Sheffield Ataxia
Centre, one of only 2 National Ataxia Centres in the UK.
To conclude, we present here clinical data of a large series
of patients with anti-GAD ataxia and highlight a significant
overlap between anti-GAD and GA. This has significant ther-
apeutic implications. We share our experience of treating
these patients with GFD and/or immunosuppression and pro-
pose that early treatment intervention is more likely to be
associated with better outcomes and limit permanent disability
even if the initial presentation suggests a mild slowly progres-
sive disease.
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